Cancer immunotherapy: Great expectations in the world of oncology but a cause for kidney concern

Nefrologia (Engl Ed). 2019 Jan-Feb;39(1):94-96. doi: 10.1016/j.nefro.2018.05.002. Epub 2018 Jun 23.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / secondary
  • Adenocarcinoma / therapy*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy*
  • Female
  • Humans
  • Ipilimumab / adverse effects*
  • Ipilimumab / therapeutic use
  • Kidney Diseases / chemically induced
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / therapy
  • Middle Aged
  • Nivolumab / adverse effects*
  • Nivolumab / therapeutic use
  • Temporal Lobe*

Substances

  • Antineoplastic Agents, Immunological
  • Ipilimumab
  • Nivolumab